Appili Therapeutics Inc. (TSX:APLI)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.32M -45.4% |
| Revenue (ttm) | 362.07K +260.5% |
| Net Income | -4.69M |
| EPS | -0.04 |
| Shares Out | 132.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0100 |
| Previous Close | 0.0100 |
| Day's Range | 0.0100 - 0.0100 |
| 52-Week Range | 0.0100 - 0.0400 |
| Beta | -0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials f... [Read more]
Financial Performance
In fiscal year 2026, Appili Therapeutics's revenue was 244,179, an increase of 143.10% compared to the previous year's 100,443. Losses were -4.24 million, 61.6% more than in 2025.
Financial StatementsNews
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Appili adopts a new business strategy that focuses on the biodefence sector Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Comp...
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for in...
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1
Appili Therapeutics to Exhibit at World Vaccine Congress Washington
Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX, Nova ...
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs
Appili Therapeutics prices 30M units at $0.025 in private placement
Appili Therapeutics (APLIF) announced a non-brokered private placement of up to approximately 30,000,000 units of the Company at a price of $0.025 per Unit for aggregate gross proceeds of up…
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships...
Appili Therapeutics, Vitalix awarded up to $40M contract from NIAID
Appili Therapeutics (APLIF) and its partner Vitalex Biosciences announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded up to $...
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for i...
Appili Therapeutics to present progress on Tularemia vaccine
Appili Therapeutics (APLIF) announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical, Biological, Radiological and Nuclear Conference, taking place ...
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference
Appili Non-Clinical Director to join NATO and allied representatives and present ATI-1701 biodefense vaccine as a potential solution to the tularemia threat Appili Non-Clinical Director to join NATO a...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million
Appili Therapeutics, colleagues publish manuscript on ATI-1701 efficacy
Appili Therapeutics (APLIF) announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled, “Vaccination with a novel...
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Peer-reviewed publication highlights ATI-1701's robust protection against aerosolized Francisella tularensis exposure in multiple animal models
Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia...
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: A...
Aditxt announces termination of arrangement agreement with Appili Therapeutics
Aditxt (ADTX) announced that it has determined it is in the best interest of the company and its stockholders to terminate the previously announced arrangement agreement with Appili Therapeutics (APLI...
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: A...
Appili Therapeutics publishes manuscript on emergency response to tularemia
Appili Therapeutics (APLIF) announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial infection. Dr. Carl Gelhaus, Ph.D., Director...
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
A review of recent findings suggests that Appili's biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks A review of recent findings suggests that Appili's biodefense vaccine...
Appili Therapeutics granted new patents for LIKMEZ
Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims protecting its oral formulation of metronidazole, LIKME...
Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ